Literature DB >> 24237851

Quality of life in non-melanoma skin cancer--the skin cancer quality of life (SCQoL) questionnaire.

Gabrielle Randskov Vinding1, Karl Bang Christensen, Solveig Esmann, Anne Braae Olesen, Gregor B E Jemec.   

Abstract

BACKGROUND: Disease-specific quality of life (QoL) questionnaires are increasingly used to provide patient-reported out-come measures in both malignant and non-malignant disease.
OBJECTIVE: To create, validate and test the psychometrics of the Skin Cancer Quality of Life (SCQoL), which was designed to measure health-related QoL in patients with non-melanoma skin cancer affecting any area and undergoing any therapy. METHODS AND MATERIALS: The SCQoL was developed in a stepwise approach. Three pilot studies (testing content and face validity) and psychometric testing (scale structure, reliability, domains and known-groups validity, concurrent and convergent validity) were conducted. Rasch analyses were performed on the final questionnaire.
RESULTS: The initial 10-item questionnaire was reduced to 9 items following interviews and inter-item correlations. The nine item scale was confirmed by Item Response Theory (IRT) and internal consistency. Differential Item Functioning (DIF) was found for a single item, but the effect was small.
CONCLUSION: The final 9-item SCQoL is unidimensional and consists of 3 domains covering function, emotions and control. Furthermore there is one single global item. The total score range from 0 to 27. Higher score denote a greater impairment of the QoL.
© 2013 by the American Society for Dermatologic Surgery, Inc. Published by Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2013        PMID: 24237851     DOI: 10.1111/dsu.12353

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


  1 in total

1.  Patient experiences and outcomes following facial skin cancer surgery: A qualitative study.

Authors:  Erica H Lee; Anne F Klassen; Jessica L Lawson; Stefan J Cano; Amie M Scott; Andrea L Pusic
Journal:  Australas J Dermatol       Date:  2015-04-02       Impact factor: 2.875

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.